Search your stocks

Share

Profile

Concord Drugs Ltd.Concord Drugs Ltd.

68(+1.22%)

1W: +1.79%

1M: +17.86%

1Y: +87.13%

Financials

Charts

YoY Net Sales

Operating Margin

EPS Growth

Pros & Cons

POSITIVES

Consistent revenue growth over the last four quarters indicates strong demand for products.
Improved gross margins due to better cost management and operational efficiency.
Increased market share in key segments reflects effective marketing and product innovation strategies.

NEGATIVES

Rising raw material costs have pressured profit margins, affecting overall profitability.
Fluctuating currency exchange rates may impact international sales and margins.
High debt levels could pose liquidity risks and limit future investments.

Quarterly Results Data

Field	Trend	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue		7.53	12.78	15.64	11.69	12.37	10.80	10.40	13.61
Expenses		6.73	13.04	16.19	11.65	12.30	10.27	10.34	13.45
Operating Profit		0.80	-0.26	-0.55	0.04	0.07	0.53	0.06	0.16
Other Income		0	0	0	0	0	0	0	0
Interest		0.43	0.50	0.50	0.45	0.47	0.50	0.61	0.49
Depreciation		0.39	0.39	0.39	0.34	0.34	0.37	0.38	0.37
Profit Before Tax		0.80	-0.26	-0.55	0.04	0.07	0.53	0.06	0.16
Tax		0.24	-0.02	-0.21	0.01	0.02	0.30	0.02	0.04
Net Profit		0.56	-0.24	-0.34	0.03	0.04	0.23	0.04	0.12
Eps in Rs		0.60	-0.24	-0.34	0.03	0.04	0.23	0.04	0.12